Clinical Operations Featured Articles

  1. Is CRA Shortage To Blame For CRO Turnover? 12/20/2016

    The results of a study on compensation released by HR+Survey Solutions (HR+SS) show that turnover in the U.S. for clinical monitoring jobs at CROs remained high in 2015. Clinical monitoring jobs, such as clinical research assistants (CRAs), involve individuals whose job function is monitoring the health of study participants in clinical trials.

  2. How Pfizer Uses Patient Video To Improve Sickle Cell Trials 12/16/2016

    Sickle cell disease is a red blood cell disorder where patients have abnormal hemoglobin in those cells. In this interview Brenda Cooperstone, VP and chief development officer for the specialty care business unit at Pfizer, discusses the efforts made to understand sickle cell patients, their condition, and how the company should interact with them during visits to the emergency room.

  3. Clinical Leader Forum: A Conference Designed For You 12/14/2016

    I attend a lot conferences and events each year focused on clinical trials. Almost all of the content revolves around high-minded topics like RBM, Big Data, and TransCelerate initiatives. While those topics are interesting for some, I speak to countless executives throughout the year who handle clinical ops for their companies. Their reality includes outsourcing trials and trying – to the best of short-staffed and underfunded situations – to manage this unwieldy process

  4. Clinical Leader Strengthens Editorial Advisory Board 12/14/2016

    In 2016 Clinical Leader added eight distinguished members of the clinical trials community to our Editorial Advisory Board. These individuals help to guide our editorial focus and direction.

  5. IN CASE YOU MISSED IT: Clinical Leader Top 3 Articles For November 2016 12/9/2016

    Below are my top three articles downloaded on Clinical Leader for the month of November 2016. In case you missed them, please take this opportunity to see what everyone else was learning about the growing clinical staff shortage, how Lilly is helping physicians become researchers, and how Duke and PatientsLikeMe are bringing a novel approach to ALS trials.

  6. Clinical News Roundup: Almac And inVentiv Health Partner On IRT 12/9/2016

    Clinical news roundup for the week of December 4, 2016 with information on Almac partnering with inVentiv on IRT, ERT acquiring Exco In Touch, and the 21st Century Cures bill passing the Senate and moving on to the White House.

  7. Novartis Approach Slashes Study Startup Time 12/8/2016

    “Study startup has essentially been the same since most folks in the pharma industry can remember,” says Stephanie Petrone, executive director, medical operations for Novartis. “The paperwork is the same and the process is the same.” But now, with standard contract language and a centralized IRB, Novartis is significantly reducing the time it takes to start a study.

  8. Helping Trump Prioritize His Clinical Trials Agenda 11/21/2016

    Scrolling through my Facebook and Twitter feed in the days immediately following the presidential election, you would think the world had just ended. The next four years will certainly be a period of change. For many, change brings uncertainty and fear. But rather than speculate on what we may or may not see over the next four years, let’s focus on what we might hope to see, and what would be best for the industry.

  9. DrugDev Enters Patient Arena With SecureConsent Acquisition 11/18/2016

    As an organization, clinical trial solution provider DrugDev has placed a focus on making the lives of site personnel easier. That mentality of servicing the site has primarily focused on interactions between sponsors and CROs and how those interactions can be improved. With its acquisition of SecureConsent, that focus now includes patients as well.

  10. Clinical News Roundup: ICH Looks To Revamp GCP Guidelines 11/18/2016

    Clinical News Roundup for the week of November 14, 2016 with information on efforts of the ICH to revamp GCP guidelines, DrugDev’s acquisition of SecureConsent, and successful outcomes resulting from an adaptive trial approach.